{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 3-[(''E'')-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
| image = Droloxifene.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 19–37 hours<ref name="OettelSchillinger2012">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA299|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|pages=158,299}}</ref><ref name="Manni1999">{{cite book|author=Andrea Manni|title=Endocrinology of Breast Cancer|url=https://books.google.com/books?id=7DSYBwAAQBAJ&pg=PA298|date=15 January 1999|publisher=Springer Science & Business Media|isbn=978-1-59259-699-7|pages=298–}}</ref>
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 82413-20-5
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 3033767
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 2298372
| UNII = 0M67U6Z98F
| KEGG = D03911
| ChEBI = 34731
| ChEMBL = 487

<!--Chemical data-->
| C=26 | H=29 | N=1 | O=2
| SMILES = CC/C(=C(/C1=CC=C(C=C1)OCCN(C)C)\C2=CC(=CC=C2)O)/C3=CC=CC=C3
| StdInChI_Ref = 
| StdInChI = 1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+
| StdInChIKey_Ref = 
| StdInChIKey = ZQZFYGIXNQKOAV-OCEACIFDSA-N
| synonyms = FK-435; ICI-79280; K-060; K-21060E; RP-60850; 3-Hydroxytamoxifen; 3-OH-TAM
}}

'''Droloxifene''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (former developmental code names '''FK-435''', '''ICI-79280''', '''K-060''', '''K-21060E''', '''RP-60850'''), also known as '''3-hydroxytamoxifen''', is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group<ref name="OettelSchillinger2012" /> that was developed originally in [[Germany]] and later in [[Japan]] for the treatment of [[breast cancer]], [[osteoporosis]] in men and [[menopause|postmenopausal women]], and [[cardiovascular disorder]]s but was abandoned and never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA472|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=472–}}</ref><ref name="MortonHall1999">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA106|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=106–}}</ref><ref name="CRAIGFurr2010">{{cite book|author1=JORDAN V. CRAIG|author2=B.J.A. Furr|title=Hormone Therapy in Breast and Prostate Cancer|url=https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA200|date=5 February 2010|publisher=Springer Science & Business Media|isbn=978-1-59259-152-7|pages=200–}}</ref><ref name="AdisInsight">http://webcache.googleusercontent.com/search?q=cache:5syveMj6PR8J:adisinsight.springer.com/drugs/800000847+&cd=1&hl=en&ct=clnk&gl=us</ref> It reached [[Phases of clinical research|phase II]] and [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for these indications before development was discontinued in 2000.<ref name="AdisInsight" /><ref name="OttowWeinmann2008">{{cite book|author1=Eckhard Ottow|author2=Hilmar Weinmann|title=Nuclear Receptors as Drug Targets|url=https://books.google.com/books?id=iATfLbPgRugC&pg=PA153|date=8 September 2008|publisher=John Wiley & Sons|isbn=978-3-527-62330-3|pages=153–}}</ref> The drug was found to be significantly less effective than tamoxifen in the treatment of breast cancer in two phase III clinical trials.<ref name="OttowWeinmann2008" /><ref name="DevitaHellman2003">{{cite book|author1=Vincent T. Devita|author2=Samuel Hellman|author3=Steven A. Rosenberg|title=Progress in Oncology 2003|url=https://books.google.com/books?id=4ipsRFlwlx0C&pg=PA217|date=1 April 2003|publisher=Jones & Bartlett Learning|isbn=978-0-7637-2064-3|pages=217–}}</ref>

Droloxifene is an [[structural analogue|analogue]] of [[tamoxifen]], specifically 3-hydroxytamoxifen, but has 10- to 60-fold increased [[affinity (pharmacology)|affinity]] for the [[estrogen receptor]]<ref name="Missailidis2008">{{cite book|author=Sotiris Missailidis|title=Anticancer Therapeutics|url=https://books.google.com/books?id=BQOWmnxcaMwC&pg=PA165|date=13 October 2008|publisher=John Wiley & Sons|isbn=978-0-470-69703-0|pages=165–}}</ref> and reduced partial [[estrogen]] [[agonist]]ic activity.<ref name="CRAIGFurr2010" /><ref name="Publishers1998">{{cite book|author=Bentham Science Publishers|title=Current Pharmaceutical Design|url=https://books.google.com/books?id=dg4ropCtzJgC&pg=PA76|date=February 1998|publisher=Bentham Science Publishers|pages=76–}}</ref> It causes a dose-dependent decrease in [[luteinizing hormone]] and [[follicle-stimulating hormone]] levels, indicating that it has [[antigonadotropic]] activity, and dose-dependently increases [[sex hormone-binding globulin]] levels, indicating that it has estrogenic activity in the [[liver]].<ref name="Manni1999" /> Similarly to tamoxifen, droloxifene has partial estrogenic effects in the [[uterus]].<ref name="MorrowJordan2003">{{cite book|author1=Monica Morrow|author2=Virgil Craig Jordan|title=Managing Breast Cancer Risk|url=https://books.google.com/books?id=HXKibhaF5lMC&pg=PA193|year=2003|publisher=PMPH-USA|isbn=978-1-55009-260-8|pages=193–}}</ref> Unlike tamoxifen, droloxifene does not produce [[DNA adduct]] or [[liver tumor]]s in animals.<ref name="Manni1999" />

==See also==
* [[Afimoxifene]] (4-hydroxytamoxifen)
* [[Endoxifen]] (''N''-desmethyl-4-hydroxytamoxifen)

==References==
{{Reflist|2}}

==External links==
* [http://webcache.googleusercontent.com/search?q=cache:5syveMj6PR8J:adisinsight.springer.com/drugs/800000847+&cd=1&hl=en&ct=clnk&gl=us Droloxifene - AdisInsight]


{{Estrogen receptor modulators}}

[[Category:Phenols]]
[[Category:Amines]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]
[[Category:Abandoned drugs]]